KalVista Pharmaceuticals Inc (NASDAQ: KALV) kicked off on Tuesday, down -4.15% from the previous trading day, before settling in for the closing price of $16.86. Over the past 52 weeks, KALV has traded in a range of $7.30-$17.28.
Annual sales at Healthcare sector company slipped by -17.63% over the past five years. While this was happening, its average annual earnings per share was recorded 87.71%. With a float of $37.78 million, this company’s outstanding shares have now reached $50.54 million.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 25.27%, while institutional ownership is 97.72%. The most recent insider transaction that took place on Dec 08 ’25, was worth 120,424. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,294 shares at a rate of $16.51, taking the stock ownership to the 424,520 shares. Before that another transaction happened on Nov 24 ’25, when Company’s Chief Commercial Officer sold 3,813 for $13.45, making the entire transaction worth $51,289. This insider now owns 39,728 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
In the latest quarterly report, which was put into the public domain on 4/30/2024, the organization reported -1.07 earnings per share (EPS), lower than consensus estimate (set at -0.72) by -0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.71% per share during the next fiscal year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Take a look at KalVista Pharmaceuticals Inc’s (KALV) current performance indicators. Last quarter, stock had a quick ratio of 7.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 571.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00 and is forecasted to reach 0.91 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
KalVista Pharmaceuticals Inc (NASDAQ: KALV) saw its 5-day average volume 2.6 million, a positive change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 87.81%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 83.70%, which indicates a significant increase from 78.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.09 in the past 14 days, which was higher than the 0.75 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.43, while its 200-day Moving Average is $12.74. Nevertheless, the first resistance level for the watch stands at $16.80 in the near term. At $17.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.79. If the price goes on to break the first support level at $15.81, it is likely to go to the next support level at $15.47. The third support level lies at $14.82 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
The company with the Market Capitalisation of 816.83 million has total of 50,546K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -183,440 K annual income. Company’s last quarter sales were recorded 13,690 K and last quarter income was -49,480 K.
